In part 1 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what happened to an earlier Abbott product, the Navigator, and explains the latest CGM products, Freestyle Libre and Freestyle Libre Pro.
Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care where he and his team are focused on designing, developing, and commercializing software-based products and services.
Transcript of this video segment:
Steve Freed — This is Steve Freed with Diabetes In Control and we’re here at the American Diabetes Association 77th scientific sessions 2017. And we’re here to present you some of really exciting interviews with some of the top endos from all across the world and we have with us a unique guest. Tell us a little bit about yourself and what you do.
Joel Goldsmith — My name is Joel Goldsmith. I lead Abbott Diabetes Care Digital Platforms Group, which is focused on software-based products and services, which are increasingly becoming important as one of the modern tools available to clinicians and patients to help manage and treat diabetes.
Steve Freed — How long have you been with Abbott?
Joel Goldsmith –Almost 10 years
Steve Freed — I don’t know if you’ll be able to answer this question, but Abbott was at the forefront of CGM before anybody. They bought a company and they had a product called Navigator. What happened to it?
Joel Goldsmith –The Feestyle Navigator story is an interesting one. It set the foundation for what we’ve introduced more recently with Freestyle Libre and freestyle Libre Pro. It certainly demonstrated to the clinical community that accuracy profile of are wired enzyme technology, which is the foundation to our sensing platform. That product embodiment wasn’t commercially viable for a number of reasons and so when we took a fresh look at a new product embodiment using that same core sensing technology, we really focused on a set of design principles, namely convenience, discretion, simplicity, affordability, and actionable information, and affordability was a big part of that because we know without making it accessible to a broad base of patients, it wasn’t going to be commercially viable and I think we’re now demonstrating that those attributes really live within Freestyle Libre and Freestyle Libre Pro because of the rapid adoption of those products.
Steve Freed — You mentioned Freestyle Libre and the Freestyle pro. A lot of people don’t even know what that is because it’s fairly new in the US. Can you explain what it is?
Joel Goldsmith — Freestyle Libre is currently under review in the U.S., but is available for use now in 35 countries, being used by over 300,000 patients for self-monitoring purposes and the simplest way to describe it is really delivering the known benefits of sensing but with a use model and a cost profile more similar to strips. So it’s being used as essentially as a replacement for strips for recurring self-monitoring without the pain and inconvenience that comes with strips. Freestyle Libre Pro is a sensor base system that’s designed for use by healthcare professionals. It enables an outpatient procedure. It’s based on the same hardware and software platform as Freestyle Libre, but it’s used really to characterize a patient’s glycemic profile so either to establish a baseline or to inform treatment changes when a patient is going from one treatment regimen to another or if a patient is experiencing adverse events or medical complications to really deeply understand with the root cause of those problems are. So, a common platform — one designed for recurring self-monitoring by patients, the other intended for use by professionals to enable an outpatient procedure.
Steve Freed — For the new one that hasn’t been approved yet, are you looking to maybe have that available this year sometime?
Joel Goldsmith –Yes, it’s currently under review by the FDA I can’t really comment on the expected timing of its availability but we’re hopeful that that will be soon.
Steve Freed — It is very interesting because CGM is probably going to replace blood glucose monitoring. It only makes sense that if you can get a reading every 3 to 5 minutes or 10 minutes even twice a day, it’s better than once a day in the morning. The physician has more information to deal with that patient whether postprandial medication time of day there’s so many variables that he doesn’t have the advantage of, so I think it’s going to actually replace and I’m sure you guys also think it’s going to replace, and that’s one of the reasons you sold your blood glucose monitoring to, I think it was Panasonic…
Joel Goldsmith –That actually wasn’t us. That was Bayer that you’re thinking of. ADC still has a thriving strip-based business also so, it’s a it’s a mix today of strip and sensor but what you’re referring to I think we all agree with that the early stages of a shift from strips to sensors and not that shift in itself is a pretty meaningful change and when you couple that with the shift from proprietary devices like traditional blood glucose monitors or the Freestyle Libre reader to commercially available consumer electronic devices, which are really becoming the preferred user interface, and then finally a shift from disconnected desktop application software to cloud-based services, those three things in combination are really positioning diabetes to take full advantage and realize the full potential of digital health.